Stanford V program for locally extensive and advanced Hodgkin lymphoma

The Memorial Sloan-Kettering Cancer Center experience

S. M. Edwards-Bennett, L. M. Jacks, Craig Moskowitz, E. J. Wu, Z. Zhang, A. Noy, C. S. Portlock, D. J. Straus, A. D. Zelenetz, J. Yahalom

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.

Original languageEnglish (US)
Article numbermdp337
Pages (from-to)574-581
Number of pages8
JournalAnnals of Oncology
Volume21
Issue number3
DOIs
StatePublished - Sep 16 2009
Externally publishedYes

Fingerprint

Hodgkin Disease
Survival
Neoplasms
Disease-Free Survival
Splenic Diseases
Radiotherapy
Guidelines
Recurrence
Drug Therapy

Keywords

  • Combined modality
  • Hodgkin lymphoma
  • Involved-field radiotherapy
  • Stanford V

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Stanford V program for locally extensive and advanced Hodgkin lymphoma : The Memorial Sloan-Kettering Cancer Center experience. / Edwards-Bennett, S. M.; Jacks, L. M.; Moskowitz, Craig; Wu, E. J.; Zhang, Z.; Noy, A.; Portlock, C. S.; Straus, D. J.; Zelenetz, A. D.; Yahalom, J.

In: Annals of Oncology, Vol. 21, No. 3, mdp337, 16.09.2009, p. 574-581.

Research output: Contribution to journalArticle

Edwards-Bennett, SM, Jacks, LM, Moskowitz, C, Wu, EJ, Zhang, Z, Noy, A, Portlock, CS, Straus, DJ, Zelenetz, AD & Yahalom, J 2009, 'Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience', Annals of Oncology, vol. 21, no. 3, mdp337, pp. 574-581. https://doi.org/10.1093/annonc/mdp337
Edwards-Bennett, S. M. ; Jacks, L. M. ; Moskowitz, Craig ; Wu, E. J. ; Zhang, Z. ; Noy, A. ; Portlock, C. S. ; Straus, D. J. ; Zelenetz, A. D. ; Yahalom, J. / Stanford V program for locally extensive and advanced Hodgkin lymphoma : The Memorial Sloan-Kettering Cancer Center experience. In: Annals of Oncology. 2009 ; Vol. 21, No. 3. pp. 574-581.
@article{521bd4186dd9445c8f21ebd9a694cb6f,
title = "Stanford V program for locally extensive and advanced Hodgkin lymphoma: The Memorial Sloan-Kettering Cancer Center experience",
abstract = "Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26{\%} had stage IV disease and 20{\%} had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90{\%} and 88{\%}, respectively. The 5-year FFS was 78{\%}. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64{\%} at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.",
keywords = "Combined modality, Hodgkin lymphoma, Involved-field radiotherapy, Stanford V",
author = "Edwards-Bennett, {S. M.} and Jacks, {L. M.} and Craig Moskowitz and Wu, {E. J.} and Z. Zhang and A. Noy and Portlock, {C. S.} and Straus, {D. J.} and Zelenetz, {A. D.} and J. Yahalom",
year = "2009",
month = "9",
day = "16",
doi = "10.1093/annonc/mdp337",
language = "English (US)",
volume = "21",
pages = "574--581",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Stanford V program for locally extensive and advanced Hodgkin lymphoma

T2 - The Memorial Sloan-Kettering Cancer Center experience

AU - Edwards-Bennett, S. M.

AU - Jacks, L. M.

AU - Moskowitz, Craig

AU - Wu, E. J.

AU - Zhang, Z.

AU - Noy, A.

AU - Portlock, C. S.

AU - Straus, D. J.

AU - Zelenetz, A. D.

AU - Yahalom, J.

PY - 2009/9/16

Y1 - 2009/9/16

N2 - Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.

AB - Background: The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data. Patients and methods: From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially ≥5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) ≥4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined. Results: The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS ≥4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years. Conclusion: Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.

KW - Combined modality

KW - Hodgkin lymphoma

KW - Involved-field radiotherapy

KW - Stanford V

UR - http://www.scopus.com/inward/record.url?scp=77949630205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949630205&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdp337

DO - 10.1093/annonc/mdp337

M3 - Article

VL - 21

SP - 574

EP - 581

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

M1 - mdp337

ER -